DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 4,867,979 Sheth Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 4,867,979 Sheth Et Al United States Patent (19) 11 Patent Number: 4,867,979 Sheth et al. 45 Date of Patent: Sep. 19, 1989 54 ANTIDIARRHEAL COMPOSITIONS AND 58 Field of Search ............... 424/195.1; 514/57, 867, USE THEREOF 514/165, 159, 222, 396, 466, 403, 420, 532, 429, (75) Inventors: Bhogilal B. Sheth, Norwalk; Sheri A. 567,568,579,553,415 Gilbert, Stratford; Jane F. Kinsel, 56) References Cited Derby, all of Conn. U.S. PATENT DOCUMENTS 73 Assignee: Richardson-Vicks Inc., Wilton, Conn. 4,588,589 5/1986 Sheth ................................ 424/195.1 21 Appl. No.: 913,755 Primary Examiner-John Rollins (22 Filed: Sep. 30, 1986 Attorney, Agent, or Firm-George W. Rauchfuss, Jr. 57 ABSTRACT Related U.S. Application Data Antidiarrheal compositions showing enhanced antidiar 62 Division of Ser. No. 646,832, Sep. 4, 1984, Pat. No. rheal activity comprise a non-steroidal anti-inflamma 4,666,716. tory drug compound and a polymeric hydroabsorptive 51 Int. Cl." ................... A61K 35/78; A61K 31/715; agent. A patient in need of remedial or preventive treat A61K 31/60; A61K 31/54 ment of diarrhea symptoms is administered an antidiarr 52 U.S. C. ................................... 424/195.1; 514/57; heally effective amount of said antidiarrheal composi 514/159; 514/165; 514/403; 514/466; 514/415; tions. 514/429; 514/532; 514/553; 514/567; 514/568; 514/579; 514/867; 514/226.5 22 Claims, 1 Drawing Sheet ISOBOLOGRAM FOR THE COMBINATION OF BUPROFEN (IBF) AND PSYLUM (PS) (HOUR POST-CHALLENGE) 300 2O O Oo IBF (mg/kg) U.S. Patent Sep. 19, 1989 4,867,979 SOBOLOGRAM FOR THE COMBINATION OF BUPROFEN (IBF) AND PSYLLUM (PS) (I HOUR POST-CHALLENGE) IBF (mg/kg) 4,867,979 1. 2 tite curb under the trademark Regal Mannan by Regal ANTDARRHEAL COMPOST ONS AND USE Vitamin Co., Costa Mesa, Calif. THEREOF The NSAID compounds whose antidiarrheal activity is potentiated by a polymeric hydroabsorptive agent of This is a division of application Ser. No. 646,832, filed this invention vary widely in their chemical structure Sept. 4, 1984, now U.S. Pat. No. 4,666,716. and in their biological profiles as analgesics, anti-inflam matory agents and antipyretic agents. Among the FIELD OF THE INVENTION classes of NSAID compounds found useful in the com This invention relates to antidiarrheal compositions positions of this invention there may be mentioned for of enhanced antidiarrheal activity and to the use thereof O example, salicylic acid derivatives, propionic acid de to treat a patient in need of preventative or remedial rivatives, indole and pyrole acetic acid derivatives, treatment of diarrhea symptoms. pyrazole derivatives, fenamate derivatives, oxicam de rivatives, phenylacetamide derivatives and the like. BACKGROUND OF THE INVENTION Among the members of this group of NSAID com Diarrhea can result from a variety of pathophysiolog 15 pounds there may be mentioned for example, aspirin, ical disorders including bacterial and parasitic infec salsalate, sodium salicylate, magnesium salicylate, acet tions, disease or debilitation of organs such as liver, aminophen, phenacetin, diflunisal, Zomepirac sodium, adrenal and others. It can also occur as a result of other ibuprofen, naproxen, fenoprofen calcium, piroxican, therapy or diet. In all cases, diarrhea is generally a flurbiprofen, mefenamic acid, sulindac, fenbufen, keto 20 profen, tolmetin sodium, indomethacin, meclofenamate symptom of organic gastrointestinal disorders and not sodium, phenylbutazone, and the like. itself a disorder. Chronic diarrhea is generally due to Especially preferred NSAID compounds in the anti intestinal hypermotility and rapid transport. It may also diarrheal compositions of this invention are aspirin, be due to, or accompanied by hypersecretion of acid indomethacin and ibuprofen. gastric juices or decreased reabsorption and may, in 25 While this invention envisions any antidiarrheally some instances, particularly those accompanied by hy effective potentiating combination combination of persecretion, be associated with emotional tension and NSAID compound and polymeric hydroabsorptive psychological conflicts. agents, the relative amounts of NSAID compound to Antidiarrheal compounds are, of course, wellknown polymeric hydroabsorptive agent in the compositions of in the medicinal arts and take various forms. In particu 30 this invention that provide the enhanced antidiarrheal lar there are a variety of products known which act activity is in the range of ratio of NSAID compound to systemically to provide antidiarrheal effects when ad polymeric hydroabsorptive agent of from about 1:30 to ministered in a manner which will enable the drug to be about 1:600, more preferably from about 1:75 to about taken into the system at effective therapeutic levels. 1:400 and most preferably from about 1:100 to about It is becoming increasingly evident from the litera 35 1:200, ture that non-steroidal anti-inflammatory drugs The compositions of the present invention can be (NSAID) are effective antidiarrheal agents, but gener prepared in forms suitable for administration to humans ally, only at high doses. It would be highly desirable, and animals by compounding an effective single dose however, if the antidiarrheal doses of the NSAID were amount of the composition of the active ingredients of much lower than-those typically reported for their anti this invention with known ingredients generally em inflammatory or analgesic activity and the antidiarrheal ployed in the preparation of therapeutic compositions activity of these NSAID could be potentiated so as to provided as tablets, capsules, lozenges, chewable loz provide more effective antidiarrheal activity. enges, pills, powder, granules, suspensions, or other SUMMARY OF THE INVENTION similar forms which can be taken orally. In general the 45 composition of the active ingredients of this invention Antidiarrheal compositions of enhanced antidiarrheal above are indicated for use as pharmacotherapeutic activity are provided by compositions of a NSAID and agents in a wide variety of mammalian conditions a polymeric hydroabsorptive agent. Administration of which require relief of diarrhea symptoms accompany an antidiarrheally effective amount of said compositions ing abnormal action of the gastrointestinal system. to patients would provide remedial or preventive treat 50 The dosage regimens in carrying out the pharmco ment of diarrhea symptoms. therapeutic methods utilizing the compositions of this invention are those which insure maximum therapeutic DETALS OF THE INVENTION response until improvement is obtained and thereafter The antidiarrheal activity of NSAID compounds has the minimum effective level which gives relief. Thus, in been found to be unexpectedly potentiated when admin 55 general, the dosages are those that are therapeutically istered concurrently with a polymeric hydroabsorptive effective in the treatment of diarrhea. In general, the agent. Preferred hydroabsorptive agents are nonionic single oral dose may contain up to the usual therapeutic polymeric hydroabsorptive agents and still more pre limit of the individual NSAID in combination with the ferred hydroabsorptive agents are psyllium and gluco appropriate amount of polymeric hydroabsorptive mannan. Especially preferred in psyllium. agent to achieve the appropriate ratios. For example, at Psyllium (plantagoe seed) useful in the compositions the 1:30 ratio, 400 mg ibuprofen might be combined of this invention is described in Pharmacopeia XX, page with 12 g polymer whereas 50 mg indomethacin might 634, U.S. Pharmacopeial Convention, Inc., 1980. be combined with 1.5g polymer. At the other extreme, Glucomannan useful in the compositions of this inven at an NSAID/polymer ratio of about 1:600, as little as 1 tion is described in the article titled “Japanese Diet 65 mg ibuprofen plug 600 mg polymer might be an effec Food” on page 22 of the September 1980 issue of Food tive dose. The preferred dose levels would be those that Engineering. Glucomannan is a hydrophilic hemicellu achieve optimal clinical antidiarrheal effectiveness at lose extract from the knojac root and is sold as an appe the lowest NSAID dose. The NSAID compound and 4,867,979 3 4. the polymeric hydroabsorptive agent may be adminis Sweetening agents, such as those set forth above, and tered concurrently or together as a single formulation. flavoring agents may be added to provide a palatable Fractional or multiple doses can of course be given oral preparation. These compositions may be preserved bearing in mind that in selecting the appropriate dosage by the addition of an anti-oxidant such as ascorbic acid. in any specific case, consideration must be given to the Dispersible powders and granules suitable for prepa patient's weight, general health, age, and other factors ration of an aqueous suspension by the addition of water which may influence response to the drug. The drug provide the active ingredients in admixture with dis response on oral administration usually follows within persing, wetting agent or suspending agents. These the first hour after administration and may be main excipients are suspending agents, for example, sodium tained for up to about 4 hours. The drug is generally O carboxymethyl cellulose, hydroxypropyl methylcellu given in single doses up to 8 times daily or as required lose, sodium alginate, polyvinylpyrrolidine, gum traga to maintain effective continuous relief of diarrhea symp canth and gun acacia; dispersing or wetting agents may toms be a naturally occurring phosphatide, for example, leci Compositions intended
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Extraction and Evaporation: Experiment 1 Separating the Components of a Mixture1 Week 1
    Organic Chemistry I Laboratory Extraction and Evaporation: Experiment 1 Separating the Components of a Mixture1 Week 1 Background Reading Zubrick, J. W. The Organic Chem Lab Survival Manual, 4th edition, Wiley & Sons, Inc., New York, 1997. Keeping a Notebook: Pg 12-24. Interpreting Handbooks: Pg 26-31, 34-44. Extraction and Washing: Pg 148-168. Background Senario One of the many places organic chemists are employed is in private laboratories associated with consulting firms. The purpose of these labs is generally to provide chemical analysis or synthesis of material for customers. The first few labs in CHM 220 will teach you the basic techniques needed to analyze and purify mixtures to determine the individual components. This first lab will involve determining the composition of a possible pharmaceutical preparation. Watchdog agencies exist which monitor the pharmaceuticals sold over the counter in the United States. These agencies will use private laboratory firms to analyze products suspected of violating enforced standards. For example, a new brand of analgesic may appear on drugstore shelves at a low price. The label indicates that the tablets were manufactured in the United States by a legitimate pharmaceutical company. However, the labels may reveal discrepancies and the appearance/quality of the tablets could lead an investigator to suspect that they might be counterfeit. Such knockoffs of a domestic product can be manufactured cheaply elsewhere and smuggled into the US, where they are sold for high profits. This laboratory exercise places you in the position of analyzing a suspected counterfeit analgesic preparation. The label on the suspected bottle lists the ingredients per tablet as aspirin (200 mg), acetaminophen (250 mg), and sucrose (50 mg).
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs Alter Nuclear Factor- Κβ in a Class Specific Manner
    Myers MJ et al. Treatment Dev Vet Pract 2020(1): 11-18. 10.33513/TDVP/2001-02 Treatments and Developments: Veterinary Practice OCIMUM Research Article Non-Steroidal Anti-Inflammatory Drugs Alter Nuclear Factor- κβ in A Class Specific Manner Abstract The capacity of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) to affect the NF-κβ dependent pathway was examined. The NSAIDs were co-cultured with RAW 264.7 cells transfected with a plasmid encoding Secreted Embryonic Alkaline Phosphatase (SEAP) under the control of NF-κβ. SEAP production was initiated by stimulating the cells with E. coli derived Lipopolysaccharide Michael J Myers*, Anne J Lewandowski and (LPS). Diclofenac, indomethacin, celecoxib, tolfenamic acid, flufenamic acid, Christine M Deaver and piroxicam inhibited SEAP production. Ketoprofen, phenylbutazone, Center for Veterinary Medicine, Office of Research aspirin, and acetaminophen did not affect SEAP production. TNFα stimulation Division of Applied Veterinary Research, USA of HEK293 cells transfected with a SEAP reporter gene under the control of NF-κβ was used to determine whether the NSAIDs were working directly on Received: 16 June 2020 the NF-κβ pathway or on TLR4 signaling. TNFα stimulated HEK293 cells Accepted: 20 July 2020 showed that diclofenac and flunixin inhibited SEAP production, but aspirin Version of Record Online: 31 July 2020 did not. Meloxicam and diclofenac both inhibited the amount of p65 released after LPS stimulation of the RAW 264.7 cells while flunixin did not affect Citation p65 release. Flunixin had no effect on an NF-κβ gel shift assay. These results demonstrate that NSAIDs in four of the six NSAID families can inhibit NF- Myers MJ, Lewandowski AJ, Deaver CM (2020) κβ pathway, albeit via different points in the pathway.
    [Show full text]
  • The Importance of COX-2 Inhibition for Aspirin Induced Asthma
    S54 Thorax 2000;55 (Suppl 2):S54–S56 Thorax: first published as 10.1136/thorax.55.suppl_2.S54 on 1 October 2000. Downloaded from The importance of COX-2 inhibition for aspirin induced asthma Alan Bennett There have been recent reviews of aspirin “specific” is used here to denote that the activ- induced asthma (AIA),12 the use of the ity is (usually) much greater against COX-2 COX-2 preferential inhibitor nimesulide in than against COX-1. Two drugs with a asthmatic patients intolerant to non-steroidal “preferential” status are nimesulide and mel- anti-inflammatory drugs (NSAIDs),3 and of oxicam, whereas two drugs that probably nimesulide in general.45 This paper discusses deserve the title “specific” are rofecoxib and the importance of inhibiting prostaglandin E2 celecoxib. (PGE2) synthesis in AIA, and the relative Nimesulide (4-nitro-2-phenoxymethane- safety of NSAIDs that preferentially inhibit sulphonanilide) is particularly important in COX-2. AIA because several studies have shown that it Aspirin and other NSAIDs cause broncho- is tolerated by most patients with the disorder constriction in about 10% of asthmatic to about the same extent as paracetamol. This subjects but NSAIDs relieve asthma in about sulphonanilide NSAID, which is eVective in 0.3%.2 This variability helps to show the com- treating a wide spectrum of inflammatory and plexity of the problem. Prostaglandins in painful conditions,7 was first marketed in 1985 human lung are formed by various tissues and and 10 years later it was found to be a cells, including bronchial muscle, epithelium, preferential inhibitor of COX-2.89Because it is and inflammatory cells,12 so the inhibition of not marketed in the USA, Japan, or the UK, prostaglandin formation can have numerous nimesulide is not well known in some parts of eVects.
    [Show full text]
  • Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System S
    Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three- Dimensional Human Liver Microphysiological System The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Tsamandouras, N., T. Kostrzewski, C. L. Stokes, L. G. Griffith, D. J. Hughes, and M. Cirit. “Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three- Dimensional Human Liver Microphysiological System.” Journal of Pharmacology and Experimental Therapeutics 360, no. 1 (October 19, 2016): 95–105. As Published http://dx.doi.org/10.1124/JPET.116.237495 Publisher American Society for Pharmacology & Experimental Therapeutics (ASPET) Version Final published version Citable link http://hdl.handle.net/1721.1/117617 Terms of Use Creative Commons Attribution-NonCommercial 4.0 International Detailed Terms http://creativecommons.org/licenses/by-nc/4.0/ Downloaded from jpet.aspetjournals.org at ASPET Journals on August 30, 2018 95 105, January 2017 – and the associ- ” http://dx.doi.org/10.1124/jpet.116.237495 c clearance, as assessed in vitro, g metabolism in the context of a J Pharmacol Exp Ther 360:95 average individual, “ Several in vitro systems have been traditionally applied to ated interindividual variability is not obtained. variability in intrinsic metaboli needstobecoupledwiththepopulationvariabilityassociated with other physiologic processes indrug vivo binding (e.g., to hepatic plasma bloodpredictions proteins, flow, etc.). at Thus, to theapproach perform population (Trame in vivo et level,results al., a are 2016) integrated systems is into pharmacology desirable,pharmacokinetic population physiologically (PBPK) where based models the (Rostami-Hodjegan, inJones and 2012; vitro Rowland-Yeo, 2013; Tsamandouras et al., 2015a,b).
    [Show full text]
  • Biochemistry. in the Article “An Erp60-Like Protein from the Filarial
    9966 Corrections Proc. Natl. Acad. Sci. USA 96 (1999) Biochemistry. In the article “An Erp60-like protein from the Immunology. In the article “Bacteria-induced neo-biosynthe- filarial parasite Dirofilaria immitis has both transglutaminase sis, stabilization, and surface expression of functional class I and protein disulfide isomerase activity” by Ramaswamy molecules in mouse dendritic cells” by Maria Rescigno, Ste- Chandrashekar, Naotoshi Tsuji, Tony Morales, Victor Ozols, fania Citterio, Clotilde The`ry, Michael Rittig, Donata Meda- and Kapil Mehta, which appeared in number 2, January 20, glini, Gianni Pozzi, Sebastian Amigorena, and Paola Ricciardi- 1998, of Proc. Natl. Acad. Sci. USA (95, 531–536), the authors Castagnoli, which appeared in number 9, April 28, 1998, of inadvertently cited the wrong GenBank accession numbers for Proc. Natl. Acad. Sci. USA (95, 5229–5234), the following four database sequences in the figure legend of a dendrogram corrections should be noted. The changes to references 33 and (Fig. 3b) on page 534. The correct accession numbers are 34 are in bold type. shown in the table below. 33. Medaglini, D., Rush, C. M., Sestini, P. & Pozzi, G. C. (1997) Vaccine 15, 1330–1337. Sequence ID Accession no. as published Correct accession no. 34. Rittig, M. G., Kuhn, K., Dechant, C. A., Gaukler, A., Modolell, RATPDI P54001 P04785 M., Ricciardi-Castagnoli, P., Krause, A. & Burmester, G. R. HUMPDI P55059 P07237 (1996) Dev. Comp. Immunol. 20, 393–406. CHICKPDI P16924 P09102 CEPDI Q10576 U95074 Pharmacology. The article “Nonsteroid drug selectives for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associ- Biophysics. In the article “Characterization of lipid bilayer ated with human gastrointestinal toxicity: A full in vitro phases by confocal microscopy and fluorescence correlation analysis” by Timothy D.
    [Show full text]
  • Drug Allergies & Cross-Sensitivities
    DRUG ALLERGIES & CROSS-SENSITIVITIES A Presentation for HealthTrust Members June 2, 2020 Vasyl Zbyrak, PharmD, PGY-1Pharmacy Resident Saint Barnabas Medical Center Kristine A. Sobolewski, PharmD, BCPS, Preceptor 2 Speaker & Preceptor Disclosures The presenter and his preceptor have no real or perceived conflicts of interest related to this presentation. Note: This program may contain the mention of suppliers, brands, products, services or drugs presented in a case study or comparative format using evidence-based research. Such examples are intended for educational and informational purposes and should not be perceived as an endorsement of any particular supplier, brand, product, service or drug. 3 Learning Objectives Pharmacists & Nurses: Distinguish the different drug class allergies and their mechanism of action Describe the most common drug allergies and characteristics of an allergic reaction Recommend alternative treatment options based on the drug allergy profile while evaluating the potential risk for the patient 4 Learning Objectives Pharmacy Technicians Identify the characteristics of an allergic reaction and common drug allergies Recognize the names of potentially inappropriate medications based on allergies and cross-sensitivities 5 Patient Case JG is 62 YO female presenting to the ED with pain 9/10. Patient was ordered morphine 4 mg IV push. Pain was relieved, but a rash appeared on her face with some flushing. Patient is not complaining of any other symptoms or shortness of breath. 6 Is the patient experiencing a drug allergy? 7 Adverse Drug Reactions A general term utilized to encompass any unwanted reaction to a medication and are broadly divided into Type A and B reactions Type A Type B • Reactions occurring in most • Drug hypersensitivity that is patients that are common relatively uncommon, rare and predictable and mostly unpredictable • Involves potential overdose, • Involves intolerances, side effects and drug idiosyncrasy, pseudoallergy interactions and drug allergies Source: Celik G, et al.
    [Show full text]
  • Aspirin and Other Anti-Inflammatory Drugs
    Thorax 2000;55 (Suppl 2):S3–S9 S3 Aspirin and other anti-inflammatory drugs Thorax: first published as 10.1136/thorax.55.suppl_2.S3 on 1 October 2000. Downloaded from Sir John Vane Historical introduction inhibiting COX, thereby reducing prosta- Salicylic acid, the active substance in plants glandin formation, providing a unifying expla- used for thousands of years as medicaments, nation for their therapeutic actions and their was synthesised by Kolbe in Germany in 1874. side eVects. This also firmly established certain MacLagan1 and Stricker2 showed that it was prostaglandins as important mediators of eVective in rheumatic fever. A few years later inflammatory disease (see reviews by Vane and sodium salicylate was also in use as a treatment Botting7 and Vane et al8). COX first cyclises for chronic rheumatoid arthritis and gout as arachidonic acid to form prostaglandin (PG) well as an antiseptic compound. G2 and the peroxidase part of the enzyme then Felix HoVman was a young chemist working reduces PGG2 to PGH2. at Bayer. Legend has it that his father, who was taking salicylic acid to treat his arthritis, Discovery of COX-2 complained to his son about its bitter taste. Over the next 20 years several groups postu- Felix responded by adding an acetyl group to lated the existence of isoforms of COX. Then salicylic acid to make acetylsalicylic acid. Rosen et al,9 studying COX in epithelial cells Heinrich Dreser, the Company’s head of phar- from the trachea, found an increase in activity macology, showed it to be analgesic, anti- of COX during prolonged cell culture.
    [Show full text]
  • Examining Product Risk in Contextmarket Withdrawal of Zomepirac As a Case Study
    Examining Product Risk in Context. Market Withdrawal of Zomepirac as a Case Study The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Ross-Degnan, Dennis. 1993. “Examining Product Risk in Context.” JAMA 270 (16) (October 27): 1937. doi:10.1001/ jama.1993.03510160055029. Published Version doi:10.1001/jama.1993.03510160055029 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:32692587 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Examining Product Risk in Context Market Withdrawal of Zomepirac as a Case Study Dennis Ross-Degnan, ScD; Stephen B. Soumerai, ScD; Eric E. Fortess, ScD, MPH; Jerry H. Gurwitz, MD Objective.\p=m-\Toexamine changes in the prescribing of analgesics after the mar- as nonsteroidal anti-inflammatory drugs ket entry and subsequent withdrawal of zomepirac sodium, a nonsteroidal anti\x=req-\ (NSAIDs). The drug was first marketed inflammatory drug (NSAID), following repeated reports of zomepirac-related deaths. in the United States by McNeil Phar¬ evaluate this natural we conducted time-series maceutical, Spring House, Pa, in No¬ Design.\p=m-\To quasi experiment, vember under the analyses to compare prescribing in two cohorts of primary care physicians from July 1980, proprietary name Zomax.5 Indications for which it 1980 1983. through September was marketed included relief of moder¬ care to Setting.\p=m-\Studyphysicians provided outpatient pharmaceutical patients ate to severe as well enrolled in the New postoperative pain, Jersey Medicaid program.
    [Show full text]
  • Metabolism of Phenacetin in the Rat
    METABOLISM OF PHENACETIN IN THE RAT CONRAD AGNELLO D'SOUZA B.Pharm. submitted in partial fulfilment of the requirements for the degree of Master of Pharmacy UNIVERSITY OF TASMANIA HOBART SEPTEMBER 1983. ‘, r \ytTL- cua biA-- 11\esi5 ekci tr vv. t1, PJiar,c\ b'Souz4 THE UNIVERSITY Of TASMANIA' LIBRARY 11L4 VI I SUMMARY The abuse of phenacetin-containing analgesic mixtures has been linked epidemiologically with nephrotoxicity and carcinogenicity in man. In addition, clinical and histopathological tests after chronic administration of phenacetin in man and animals have indicated that it is nephrotoxic and carcinogenic. Furthermore, it has a chemical similarity to other known carcinogenic arylamides. However, the induction of toxicity with phenacetin remains a controversial subject. A number of chronic dosing studies with phenacetin have been carried out to demonstrate the ability of the drug to induce carcinogenesis and nephropathy. However, none have sought to explain the reasons for the chronic nature of phenacetin toxicity on the basis of the increased formation of toxic metabolites after continued administration of the drug. In the present chronic daily-dosing study with phenacetin in the rat, the metabolism of the drug was monitored by analysing urine samples at regular weekly intervals. Particular attention was paid to the formation of N-hydroxyphenacetin, which has been implicated in phenacetin carcinogenicity. The metabolism of phenacetin was monitored in five groups of Hooded Wistar rats. Each group was subjected to a different treatment. The purpose was to elucidate the effects of the size of the dose, duration of treatment, influence of commonly co- administered drugs (aspirin, caffeine) and the influence of a sulfation inhibitor (pentachlorophenol) on the metabolism of phenace tin.
    [Show full text]
  • Single Dose of Diclofenac Or Meloxicam for Control of Pain, Facial Swelling, and Trismus in Oral Surgery
    Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 (1):e127-34. Diclofenac versus meloxicam in oral surgery Journal section: Oral Surgery doi:10.4317/medoral.20925 Publication Types: Research http://dx.doi.org/doi:10.4317/medoral.20925 Single dose of diclofenac or meloxicam for control of pain, facial swelling, and trismus in oral surgery Mariana Orozco-Solís 1, Yazmín García-Ávalos 2, Celeste Pichardo-Ramírez 2, Francisco Tobías-Azúa 2, Juan-Ramón Zapata-Morales 3, Othoniel-Hugo Aragon-Martínez 4, Mario-Alberto Isiordia-Espinoza 5 1 DDS, Departamento de Estomatología, Unidad Médica Familiar No. 02, Instituto Mexicano del Seguro Social, Delegación San Luis Potosí, S.L.P., México 2 DDS, Departamento de Investigación y Postgrado, Escuela de Odontología, Universidad Cuauhtémoc, plantel San Luis Poto- sí, S.L.P., México 3 MSc, PhD, Departamento de Farmacia, División de Ciencias Naturales y Exactas, Universidad de Guanajuato, Guanajuato, México 4 MSc, PhD, Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, S.L.P., México 5 DDS, MSc, PhD, Departamento de Farmacología, Facultad de Odontología, Universidad Autónoma de Baja California, Mexi- cali, México Orozco-Solís M, García-Ávalos Y, Pichardo-Ramírez C, Tobías-Azúa F, Zapata-Morales JR, Aragon-Martínez OH, Isiordia-Espinoza MA. Single Correspondence: dose of diclofenac or meloxicam for control of pain, facial swelling, and Facultad de Odontología trismus in oral surgery. Med Oral Patol Oral Cir Bucal. 2016 Jan 1;21 Universidad Autónoma de Baja California (1):e127-34. Calle Zotoluca y Chinampas s/n http://www.medicinaoral.com/medoralfree01/v21i1/medoralv21i1p127.pdf Fraccionamiento Calafia C.P.
    [Show full text]
  • Inflammatory Drugs and the Frequency
    doi: 10.1111/fcp.12463 ORIGINAL Cyclo-oxygenase selectivity and chemical ARTICLE groups of nonsteroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase Mohammad Bakhriansyaha,b , Ronald H.B. Meybooma, Patrick C. Souvereina, Anthonius de Boera, Olaf H. Klungela* aDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80082 3508 TB, Utrecht, The Netherlands bDepartment of Pharmacology, Medical Faculty, Lambung Mangkurat University, Jalan Veteran No. 128, 70232 Banjarmasin, South Kalimantan, Indonesia Keywords ABSTRACT a sulfonamide functional group, To date, no reports of hypersensitivity reactions (HSRs) among nonsteroidal chemical groups, anti-inflammatory drugs (NSAIDs) according to cyclo-oxygenase (COX) selectivity cyclo-oxygenase selectivity, and chemical groups have been published in a single study. The present study hypersensitivity reactions, assessed the reporting frequency of HSRs for NSAIDs based on their relative inhibi- nonsteroidal anti-inflamma- tory potency toward COX enzymes and chemical groups, including the presence/ tory drugs, absence of a functional sulfonamide group, in strata observed 5 years after market spontaneous reporting authorization. A case/noncase study was performed among individual case safety reports (ICSRs) with NSAIDs as suspected drugs in VigiBase, the WHO spontaneous Received 9 November 2018; reporting database. Cases were ICSRs mentioning angioedema and anaphylactic/ revised 18 February 2019; anaphylactoid shock conditions, while noncases were ICSRs without HSRs. NSAIDs accepted 8 March 2019 were categorized into (i) NSAIDs with high COX-2 selectivity (coxibs), (ii) noncoxib NSAIDs with COX-2 preference, (iii) NSAIDs with poor selectivity, or (iv) NSAIDs *Correspondence and reprints: with unknown selectivity.
    [Show full text]